AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39163972 — intervention group
Group type: EXPERIMENTAL
Intervention: Total polyphenol intake (∼914 mg/1000 kcal/d)
Number of subjects: 350
Study 39163972 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenol lipids
Number of subjects: 350
Study 39163972 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylpropanoic acids
Number of subjects: 350
Study 39163972 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnamic acids and derivatives
Number of subjects: 350
Study 39163973 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole wheat bread
Number of subjects: 5
Study 39163976 — intervention group
Group type: EXPERIMENTAL
Intervention: LC → LF diet
Number of subjects: 20
Study 39163976 — intervention group
Group type: COMPARATOR
Intervention: UPF → MPF diet
Number of subjects: 20
Study 39163976 — intervention group
Group type: COMPARATOR
Intervention: MPF → UPF diet
Number of subjects: 20
Study 39164041 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary cytoreductive surgery followed by platinum-based chemotherapy plus or minus bevacizumab
Number of subjects: 124
Study 39164041 — intervention group
Group type: COMPARATOR
Intervention: Platinum-based chemotherapy plus or minus bevacizumab alone
Number of subjects: 124
Study 39164062 — intervention group
Group type: EXPERIMENTAL
Intervention: Active care
Number of subjects: 242
Study 39164062 — intervention group
Group type: COMPARATOR
Intervention: Comfort care
Number of subjects: 242
Study 39164062 — intervention group
Group type: COMPARATOR
Intervention: Other
Number of subjects: 242
Study 39164062 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal consult
Number of subjects: 242
Study 39164062 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary decision-maker
Number of subjects: 242
Study 39164062 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant alive at survey completion
Number of subjects: 242
Study 39164067 — intervention group
Group type: EXPERIMENTAL
Intervention: apremilast 30 mg two times per day
Number of subjects: 308
Study 39164067 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 308
Study 39164167 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum mid-infrared spectroscopy (MIRS)
Number of subjects: 108
Study 39164233 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet Reactivity ExpreSsion Score (PRESS) with hyperreactive platelet response (>60% aggregation) to 0.4 µM epinephrine
Number of subjects: 129
Study 39164233 — intervention group
Group type: EXPERIMENTAL
Intervention: PRESS score above the median
Number of subjects: 129
Study 39164233 — intervention group
Group type: EXPERIMENTAL
Intervention: PRESS (cross-validation)
Number of subjects: 129
Study 39164233 — intervention group
Group type: EXPERIMENTAL
Intervention: PRESS (validation in healthy participants)
Number of subjects: 129
Study 39164407 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosutinib (starting dose: 500 mg QD)
Number of subjects: 163
Study 39164518 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen receptor pathway inhibitors (ARPIs)
Number of subjects: 218
Study 39164518 — intervention group
Group type: COMPARATOR
Intervention: Taxanes
Number of subjects: 218
Study 39164518 — intervention group
Group type: COMPARATOR
Intervention: Physician's choice
Number of subjects: 218
Study 39164557 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunct opicapone 50 mg
Number of subjects: 0
Study 39164557 — intervention group
Group type: COMPARATOR
Intervention: Levodopa 100 mg
Number of subjects: 0
Study 39164613 — intervention group
Group type: EXPERIMENTAL
Intervention: Transforaminal epidural injections (TEI)
Number of subjects: 388
Study 39164634 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary Care Behavioral Health (PCBH) model implemented in 24 primary care centres
Number of subjects: 72
Study 39164634 — intervention group
Group type: COMPARATOR
Intervention: Standard care in 48 primary care centres
Number of subjects: 72
Study 39164673 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-valent pneumococcal conjugate vaccine (PCV10)
Number of subjects: 1000
Study 39164673 — intervention group
Group type: COMPARATOR
Intervention: Control group (children without pneumonia)
Number of subjects: 1000
Study 39164727 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding (BF)
Number of subjects: 408
Study 39164727 — intervention group
Group type: COMPARATOR
Intervention: Formula feeding (FF)
Number of subjects: 408
Study 39164727 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention to promote breastfeeding, nutrition, and sustainability
Number of subjects: 408
Study 39164770 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Alcohol Intervention (BAI)
Number of subjects: 564
Study 39164770 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 564
Study 39164808 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day vonoprazan-based triple therapy with high-dose amoxicillin (VAC-7)
Number of subjects: 628
Study 39164808 — intervention group
Group type: COMPARATOR
Intervention: 14-day extended sequential therapy (S-14)
Number of subjects: 628
Study 39164924 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab added to standard of care chemoradiation
Number of subjects: 0
Study 39164924 — intervention group
Group type: COMPARATOR
Intervention: Standard of care chemoradiation
Number of subjects: 0
Study 39164933 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) - 25 weekly sessions including behavioural activation, behaviour management, interventions for the caregiver, reminiscence, couples counselling, and cognitive restructuring
Number of subjects: 41
Study 39164933 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT)
Number of subjects: 41
Study 39164933 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 41
Study 39165152 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryo-pneumatic compression
Number of subjects: 200
Study 39165152 — intervention group
Group type: COMPARATOR
Intervention: Standard care (including standard cryotherapy)
Number of subjects: 200
Study 39165177 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 127
Study 39165177 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical treatment
Number of subjects: 127
Study 39165278 — intervention group
Group type: EXPERIMENTAL
Intervention: hAECs transplantation (hAECT)
Number of subjects: 35
Study 39165373 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening LAMA administration
Number of subjects: 10013
Study 39165373 — intervention group
Group type: COMPARATOR
Intervention: Morning LAMA administration
Number of subjects: 10013
Study 39165398 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly diagnosed axSpA
Number of subjects: 0
Study 39165398 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient self-reported assessments
Number of subjects: 0
Study 39165487 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative NEC (Bell's stage ≥2)
Number of subjects: 0
Study 39165487 — intervention group
Group type: COMPARATOR
Intervention: No postoperative NEC
Number of subjects: 0
Study 39165498 — intervention group
Group type: EXPERIMENTAL
Intervention: cfDNA methylation-based lung cancer screening model
Number of subjects: 465
Study 39165498 — intervention group
Group type: EXPERIMENTAL
Intervention: protein model
Number of subjects: 465
Study 39165498 — intervention group
Group type: EXPERIMENTAL
Intervention: mutation model
Number of subjects: 465
Study 39165498 — intervention group
Group type: EXPERIMENTAL
Intervention: final screening model (cfDNA methylation and protein features)
Number of subjects: 465
Study 39165498 — intervention group
Group type: EXPERIMENTAL
Intervention: multi-omics screening model
Number of subjects: 465
Study 39165498 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-aided pulmonary nodules diagnostic model (cfDNA methylation and CT images features)
Number of subjects: 465
Study 39165810 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial coinfections present during hospitalization for COVID-19 variants (Alpha, Delta, Omicron)
Number of subjects: 21186
Study 39165810 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta variant with bacterial coinfections
Number of subjects: 21186
Study 39165810 — intervention group
Group type: EXPERIMENTAL
Intervention: All variants with bacterial coinfections
Number of subjects: 21186
Study 39165810 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta variant
Number of subjects: 21186
Study 39166323 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary behavior reduction intervention
Number of subjects: 271
Study 39166323 — intervention group
Group type: COMPARATOR
Intervention: No-contact control group
Number of subjects: 271
Study 39166322 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Diabetes Care Model with Continuous Glucose Monitoring
Number of subjects: 0
Study 39166327 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine (0.5 mg once daily)
Number of subjects: 128
Study 39166327 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 39166332 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-Based Telemedicine Assessment by General Practitioners
Number of subjects: 0
Study 39166332 — intervention group
Group type: COMPARATOR
Intervention: Face-to-Face Consultations with Specialists
Number of subjects: 0
Study 39166425 — intervention group
Group type: COMPARATOR
Intervention: SHR-2004 (0.1, 0.3, or 1.0 mg/kg) administered intravenously (i.v.)
Number of subjects: 64
Study 39166425 — intervention group
Group type: COMPARATOR
Intervention: SHR-2004 (0.5, 1.0, 3.0, or 4.5 mg/kg) administered subcutaneously (s.c.)
Number of subjects: 64
Study 39166425 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 39166465 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppression withdrawal (ISW) at a median of 7.4 weeks before graft hysterectomy (Hx)
Number of subjects: 6
Study 39166465 — intervention group
Group type: EXPERIMENTAL
Intervention: Graft hysterectomy (Hx)
Number of subjects: 6
Study 39166663 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression stockings
Number of subjects: 63
Study 39166663 — intervention group
Group type: COMPARATOR
Intervention: Placebo stockings
Number of subjects: 63
Study 39166750 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher hepatic glucose production (HGP-insulin)
Number of subjects: 450
Study 39166750 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower % suppression of HGP
Number of subjects: 450
Study 39166750 — intervention group
Group type: EXPERIMENTAL
Intervention: HGP-basal, M-low, and M-high
Number of subjects: 450
Study 39166791 — intervention group
Group type: EXPERIMENTAL
Intervention: CT1812
Number of subjects: 0
Study 39167110 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative orthosis (CO) for 6 weeks
Number of subjects: 62
Study 39167110 — intervention group
Group type: COMPARATOR
Intervention: No orthosis (NO)
Number of subjects: 62
Study 39167110 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative orthosis (CO)
Number of subjects: 62
Study 39167148 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg tablet of selvigaltin under fasted conditions
Number of subjects: 13
Study 39167148 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg tablet of selvigaltin under fed conditions
Number of subjects: 13
Study 39167148 — intervention group
Group type: COMPARATOR
Intervention: 50 mg capsule of selvigaltin under fasted conditions
Number of subjects: 13
Study 39167148 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments of selvigaltin (tablet and capsule)
Number of subjects: 13
Study 39167241 — intervention group
Group type: EXPERIMENTAL
Intervention: SOFA score, SpO2, and respiratory effort signals
Number of subjects: 346
Study 39167241 — intervention group
Group type: COMPARATOR
Intervention: ROX index
Number of subjects: 346
Study 39167305 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbable gelatin sponge (AGS)
Number of subjects: 98
Study 39167305 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gel with AGS
Number of subjects: 98
Study 39167305 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid with AGS
Number of subjects: 98
Study 39167305 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 98
Study 39167348 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax treatment
Number of subjects: 129
Study 39167348 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax treatment with concomitant rituximab
Number of subjects: 129
Study 39167348 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax treatment with 1 prior line of therapy
Number of subjects: 129
Study 39167348 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax treatment with ≥ 2 prior lines of therapy
Number of subjects: 129
Study 39167366 — intervention group
Group type: EXPERIMENTAL
Intervention: Zasocitinib 2 mg
Number of subjects: 259
Study 39167366 — intervention group
Group type: EXPERIMENTAL
Intervention: Zasocitinib 5 mg
Number of subjects: 259
Study 39167366 — intervention group
Group type: EXPERIMENTAL
Intervention: Zasocitinib 15 mg
Number of subjects: 259
Study 39167366 — intervention group
Group type: EXPERIMENTAL
Intervention: Zasocitinib 30 mg
Number of subjects: 259
Study 39167366 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 259
Study 39167366 — intervention group
Group type: EXPERIMENTAL
Intervention: Zasocitinib (all doses)
Number of subjects: 259
Study 39167421 — intervention group
Group type: EXPERIMENTAL
Intervention: CBD (300 mg) and terpenes (1 mg each of linalool, myrcene, phytol, limonene, α-terpinene, α-terpineol, α-pinene, and β-caryophyllene)
Number of subjects: 125
Study 39167421 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 39167443 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspired video game intervention
Number of subjects: 48
Study 39167533 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous PTH (1-34) infusion
Number of subjects: 10
Study 39167533 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 patients with primary hyperparathyroidism and 10 healthy volunteers)
Number of subjects: 10
Study 39167741 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized chemotherapy based on tumor marker decline
Number of subjects: 0
Study 39167741 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 39167748 — intervention group
Group type: COMPARATOR
Intervention: Any migraine
Number of subjects: 39312
Study 39167748 — intervention group
Group type: COMPARATOR
Intervention: Migraine with aura
Number of subjects: 39312
Study 39167748 — intervention group
Group type: COMPARATOR
Intervention: Migraine without aura
Number of subjects: 39312
Study 39167748 — intervention group
Group type: COMPARATOR
Intervention: History of migraine
Number of subjects: 39312
Study 39167748 — intervention group
Group type: COMPARATOR
Intervention: Migraine frequency less than monthly
Number of subjects: 39312
Study 39167764 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive systematic hemophilia carrier screening
Number of subjects: 900
Study 39167766 — intervention group
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Number of subjects: 0
Study 39167766 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39167788 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-Term Diesel Exhaust Exposure
Number of subjects: 0
Study 39167788 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 39167806 — intervention group
Group type: EXPERIMENTAL
Intervention: Child azithromycin group
Number of subjects: 382586
Study 39167806 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 382586
Study 39167806 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant azithromycin group
Number of subjects: 382586
Study 39167807 — intervention group
Group type: EXPERIMENTAL
Intervention: Belzutifan (120 mg orally once daily)
Number of subjects: 746
Study 39167807 — intervention group
Group type: COMPARATOR
Intervention: Everolimus (10 mg orally once daily)
Number of subjects: 746
Study 39168179 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth failure defined as a weight z-score of -1.8 or below at 36 weeks PMA
Number of subjects: 5393
Study 39168179 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth faltering defined as a weight z-score decline of 1.1 or greater from birth to 36 weeks PMA
Number of subjects: 5393
Study 39168179 — intervention group
Group type: EXPERIMENTAL
Intervention: Length z-score less than -1 at 36 weeks PMA
Number of subjects: 5393
Study 39168179 — intervention group
Group type: EXPERIMENTAL
Intervention: Head circumference z-score decline of 2.43 or greater from birth to 36 weeks PMA
Number of subjects: 5393
Study 39168179 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard definitions for risk detection of cognitive impairment
Number of subjects: 5393
Study 39168179 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring length and head circumference z-scores
Number of subjects: 5393
Study 39168180 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive Sleep Apnea (OSA)
Number of subjects: 656
Study 39168180 — intervention group
Group type: EXPERIMENTAL
Intervention: Central Sleep Apnea (CSA)
Number of subjects: 656
Study 39168180 — intervention group
Group type: COMPARATOR
Intervention: Control (no to mild sleep apnea)
Number of subjects: 656
Study 39168356 — intervention group
Group type: EXPERIMENTAL
Intervention: SABR
Number of subjects: 90
Study 39168356 — intervention group
Group type: COMPARATOR
Intervention: SOC
Number of subjects: 90
Study 39168360 — intervention group
Group type: EXPERIMENTAL
Intervention: Condoliase (1.25 units)
Number of subjects: 352
Study 39168360 — intervention group
Group type: COMPARATOR
Intervention: Sham injection
Number of subjects: 352
Study 39168564 — intervention group
Group type: EXPERIMENTAL
Intervention: Olpasiran 75 mg Q12W
Number of subjects: 281
Study 39168564 — intervention group
Group type: EXPERIMENTAL
Intervention: Olpasiran 225 mg Q12W
Number of subjects: 281
Study 39168564 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 281
Study 39168591 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous rhythm monitoring
Number of subjects: 349
Study 39168901 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitravatinib (MGCD516)
Number of subjects: 48
Study 39168946 — intervention group
Group type: EXPERIMENTAL
Intervention: PwPOMS
Number of subjects: 25
Study 39168946 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 25
Study 39168966 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab and Bevacizumab (AtzBev)
Number of subjects: 0
Study 39169033 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 0
Study 39169058 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune killer cells (IKC) infusion weekly for 24 weeks
Number of subjects: 26
Study 39169058 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune killer cells (IKC) infusion
Number of subjects: 26
Study 39169095 — intervention group
Group type: EXPERIMENTAL
Intervention: Invisalign SmileView simulation
Number of subjects: 24
Study 39169095 — intervention group
Group type: EXPERIMENTAL
Intervention: Invisalign treatment with upper and lower aligners (average treatment time of 18 ± 6 months)
Number of subjects: 24
Study 39169095 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative assessment of smile parameters
Number of subjects: 24
Study 39169095 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative assessment of maxillary inter canine width
Number of subjects: 24
Study 39169095 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative assessment of lip line
Number of subjects: 24
Study 39169095 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative assessment of most posterior tooth display, smile arc, and lower incisor exposure
Number of subjects: 24
Study 39169297 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental high power radiofrequency ablation (RFA) with multi-electrodes
Number of subjects: 110
Study 39169298 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day postoperative antibiotic therapy (piperacillin/tazobactam)
Number of subjects: 0
Study 39169298 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic prophylaxis
Number of subjects: 0
Study 39169349 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment group using the Dialogue Support
Number of subjects: 0
Study 39169349 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical treatment group using the Dialogue Support
Number of subjects: 0
Study 39169349 — intervention group
Group type: COMPARATOR
Intervention: Retrospective matched control group (no Dialogue Support)
Number of subjects: 0
Study 39169350 — intervention group
Group type: EXPERIMENTAL
Intervention: Immobilisation for 0 weeks (Group A)
Number of subjects: 1088
Study 39169350 — intervention group
Group type: EXPERIMENTAL
Intervention: Immobilisation for 2 weeks (Group B)
Number of subjects: 1088
Study 39169350 — intervention group
Group type: COMPARATOR
Intervention: Immobilisation for 4 weeks (Group C)
Number of subjects: 1088
Study 39169350 — intervention group
Group type: COMPARATOR
Intervention: Immobilisation for 6 weeks (Group D)
Number of subjects: 1088
Study 39169350 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (A, B, C, D)
Number of subjects: 1088
Study 39169353 — intervention group
Group type: EXPERIMENTAL
Intervention: Soymilk (500 mL daily, 22 g soy protein, 17.2 g or 6.9 g/250 mL added sugars)
Number of subjects: 504
Study 39169395 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical PIP joint denervation
Number of subjects: 90
Study 39169395 — intervention group
Group type: COMPARATOR
Intervention: Patient education and exercise program
Number of subjects: 90
Study 39169663 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave lithotripsy (P-ESWL) followed by endoscopic retrograde cholangiopancreatography (ERCP)
Number of subjects: 2071
Study 39169699 — intervention group
Group type: EXPERIMENTAL
Intervention: PEERS® program (treatment group, n=10)
Number of subjects: 21
Study 39169827 — intervention group
Group type: COMPARATOR
Intervention: DS-7011a (anti-TLR7 monoclonal antibody) administered intravenously (IV) and subcutaneously (SC) in a 6:2 ratio against placebo.
Number of subjects: 80
Study 39169827 — intervention group
Group type: COMPARATOR
Intervention: DS-7011a (anti-TLR7 monoclonal antibody) administered IV and SC.
Number of subjects: 80